TerrAscend (TSNDF) FCF Payout Ratio (2022 - 2023)
TerrAscend (TSNDF) posted quarterly FCF Payout Ratio of 3.82 for Q4 2023, down 58917.75% year-over-year from N/an in Q4 2022, and down 1070.2% quarter-over-quarter from 0.39 in Q3 2023.
TerrAscend (TSNDF) FCF Payout Ratio (2022 - 2023) Analysis & Trends
TerrAscend (TSNDF) has reported FCF Payout Ratio for 2 consecutive years, with 3.82 the latest figure, recorded in Q4 2023.
- In Q4 2023, FCF Payout Ratio fell 58917.75% year-over-year to 3.82; the TTM figure through Dec 2023 stood at 0.15 (changed N/A YoY), while the FY2022 annual figure was 0.03, changed N/A from the prior year.
- FCF Payout Ratio fell to 3.82 in Q4 2023 per TSNDF's latest filing, from 0.39 in the prior quarter.
- Across five years, FCF Payout Ratio topped out at 0.39 in Q3 2023 and bottomed at 3.82 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 0.41 |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -0.83 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.42 |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | TerrAscend | 182.53 Mn | 140.41 Mn | 36.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -3.82 |
| Sep 30, 2023 | 0.39 |
| Dec 31, 2022 | -0.01 |